

(In millions, except per share amounts)	First Quarter		Second Quarter		Third Quarter		Fourth Quarter			Total Year
2017	(a)		(a) (b) (c) (d)		(a)		(a) (e) (f) (g) (h)
Product revenues, net	$	2,380.1	$	2,639.7	$	2,622.5	$	2,712.4		$	10,354.7
Revenues from anti-CD20 therapeutic programs	$	340.6	$	397.1	$	406.5	$	415.0		$	1,559.2
Other revenues	$	90.0	$	41.6	$	48.8	$	179.6		$	360.0
Total revenues	$	2,810.7	$	3,078.4	$	3,077.8	$	3,307.0		$	12,273.9
Gross profit (1)	$	2,426.1	$	2,712.2	$	2,707.8	$	2,797.8		$	10,643.9
Net income	$	747.5	$	862.8	$	1,226.1	$	(166.3	)	$	2,670.1
Net income attributable to Biogen Inc.	$	747.6	$	862.8	$	1,226.1	$	(297.4	)	$	2,539.1
Net income per share:
Basic earnings per share attributable to Biogen Inc.	$	3.47	$	4.07	$	5.80	$	(1.41	)	$	11.94
Diluted earnings per share attributable to Biogen Inc.	$	3.46	$	4.07	$	5.79	$	(1.40	)	$	11.92
Weighted-average shares used in calculating:
Basic earnings per share attributable to Biogen Inc.	215.6		211.9		211.4		211.5			212.6
Diluted earnings per share attributable to Biogen Inc.	215.9		212.2		211.8		212.0			213.0



(In millions, except per share amounts)	First Quarter		Second Quarter		Third Quarter		Fourth Quarter		Total Year
2016			(i)		(i) (j)		(i) (k) (l)
Product revenues, net	$	2,309.4	$	2,466.0	$	2,539.6	$	2,502.9	$	9,817.9
Revenues from anti-CD20 therapeutic programs	$	329.5	$	349.2	$	317.6	$	318.2	$	1,314.5
Other revenues	$	87.9	$	79.0	$	98.6	$	50.9	$	316.4
Total revenues	$	2,726.8	$	2,894.2	$	2,955.8	$	2,872.0	$	11,448.8
Gross profit (1)	$	2,413.8	$	2,523.9	$	2,538.9	$	2,493.5	$	9,970.1
Net income	$	969.2	$	1,048.4	$	1,030.2	$	647.9	$	3,695.7
Net income attributable to Biogen Inc.	$	970.9	$	1,049.8	$	1,032.9	$	649.2	$	3,702.8
Net income per share:
Basic earnings per share attributable to Biogen Inc.	$	4.44	$	4.79	$	4.72	$	3.00	$	16.96
Diluted earnings per share attributable to Biogen Inc.	$	4.43	$	4.79	$	4.71	$	2.99	$	16.93
Weighted-average shares used in calculating:
Basic earnings per share attributable to Biogen Inc.	218.9		219.1		218.9		216.6		218.4
Diluted earnings per share attributable to Biogen Inc.	219.3		219.4		219.4		217.0		218.8

(1) Gross profit is calculated as total revenues less cost of sales, excluding amortization of acquired intangible assets.


(a)	Net income and net income attributable to Biogen Inc. for the first, second, third and fourth quarters of 2017 include a pre-tax charge of $353.6 million, $29.4 million, $30.4 million and $30.8 million, respectively, related to our U.S. and rest of world licenses to Forward Pharma's intellectual property, including Forward Pharma's intellectual property related to TECFIDERA.


(b)	Net income and net income attributable to Biogen Inc. for the second quarter of 2017 includes a pre-tax charge to research and development expense of $300.0 million for an upfront payment to BMS upon the closing of our agreement to exclusively license BIIB092.


(c)	Net income and net income attributable to Biogen Inc. for the second quarter of 2017 includes a pre-tax charge to acquired in-process research and development of $120.0 million for an upfront payment to Remedy upon closing of the asset purchase transaction.


(d)	Net income and net income attributable to Biogen Inc. for the second quarter of 2017 includes a pre-tax charge to research and development expense of $60.0 million for a developmental milestone that became payable to the former shareholders of iPierian upon dosing of the first patient in the Phase 2 PSP study for BIIB092.


(e)	Net income attributable to Biogen Inc., for the fourth quarter of 2017, includes a pre-tax charge to noncontrolling interest of $150.0 million for a payment to Neurimmune in exchange for a 15% reduction in royalty rates payable on potential commercial sales of aducanumab.


(f)	Net income and net income attributable to Biogen Inc. for the fourth quarter of 2017 includes pre-tax charges to research and development expense of $28.0 million and $50.0 million for an upfront payment and a continuation payment, respectively, to Alkermes.


(g)	Net income and net income attributable to Biogen Inc. for the fourth quarter of 2017 includes a pre-tax charge to research and development expense of $25.0 million for an upfront payment to Ionis upon entering into a new collaboration agreement to identify new antisense-oligonucleotide drug candidates for the treatment of SMA.


(h)	Net income and net income attributable to Biogen Inc. for the fourth quarter of 2017 includes $1,173.6 million related to the provisions of the 2017 Tax Act, including a $989.6 million expense under the Transition Toll Tax.

(i)

Net income and net income attributable to Biogen Inc. for the second, third and fourth quarters of 2016 includes additional pre-tax depreciation expense totaling $15.8 million, $15.7 million and $14.0 million, respectively, as part of our decision to cease manufacturing and vacate our small-scale biologics manufacturing facility in Cambridge, MA as well as close and vacate our warehouse space in Somerville, MA.


(j)	Net income and net income attributable to Biogen Inc. for the third quarter of 2016 includes a pre-tax charge to research and development expense of $75.0 million for a license fee paid to Ionis as we exercised our option to develop and commercialize SPINRAZA.


(k)	Net income and net income attributable to Biogen Inc. for the fourth quarter of 2016 includes a pre-tax charge to research and development expense of $50.0 million for a milestone payment due to Eisai related to the initiation of a Phase 3 trial for E2609.


(l)	Net income and net income attributable to Biogen Inc. for the fourth quarter of 2016 includes a pre-tax charge of $454.8 million related to our January 2017 settlement and license agreement with Forward Pharma.